Advances in the understanding of delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage by Flynn, Liam & Andrews, Peter
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Advances in the understanding of delayed cerebral ischaemia
after aneurysmal subarachnoid haemorrhage
Citation for published version:
Flynn, L & Andrews, P 2015, 'Advances in the understanding of delayed cerebral ischaemia after
aneurysmal subarachnoid haemorrhage'  F1000Research.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
 F1000Research
Publisher Rights Statement:
 Copyright:  © 2015 Flynn L and Andrews P. This is an open access article distributed under the terms of the
Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
F1000Research
Open Peer Review
, John Radcliffe HospitalKyle Pattinson
UK, , John RadcliffeMatthew Rowland
Hospital UK
, Mount Sinai MedicalStephan Mayer
Center, New York USA
, WashingtonMichael N. Diringer
University School of Medicine USA
, University of MunichNikolaus Plesnila
Medical Center Germany
Discuss this article
 (0)Comments
4
3
2
1
REVIEW
Advances in the understanding of delayed cerebral ischaemia
 after aneurysmal subarachnoid haemorrhage [version 1;
referees: 4 approved]
Liam Flynn, Peter Andrews
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
Abstract
Delayed cerebral ischaemia has been described as the single most important
cause of morbidity and mortality in patients who survive the initial aneurysmal
subarachnoid haemorrhage. Our understanding of the pathophysiology of
delayed cerebral ischaemia is meagre at best and the calcium channel blocker
nimodipine remains the only intervention to consistently improve functional
outcome after aneurysmal subarachnoid haemorrhage. There is substantial
evidence to support cerebral vessel narrowing as a causative factor in delayed
cerebral ischaemia, but contemporary research demonstrating improvements
in vessel narrowing has failed to show improved functional outcomes. This has
encouraged researchers to investigate other potential causes of delayed
cerebral ischaemia, such as early brain injury, microthrombosis, and cortical
spreading depolarisation. Adherence to a common definition of delayed
cerebral ischaemia is needed in order to allow easier assessment of studies
using multiple different terms. Furthermore, improved recognition of delayed
cerebral ischaemia would not only allow for faster treatment but also better
assessment of interventions. Finally, understanding nimodipine’s mechanism of
action may allow us to develop similar agents with improved efficacy.
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Introduction
Aneurysmal subarachnoid haemorrhage (aSAH) has an incidence 
of 6–11 per 100,000 people per year and accounts for only 5% of all 
strokes1–4. Despite this, aSAH is the cause of one third of all stroke-
related years of potential life lost before the age of 655. Approxi-
mately 70% of all people with aSAH will either die or require 
help with activities of daily living at six months after the initial 
injury5. The mean age of onset of aSAH is 55 years and, when com-
bined with its poor morbidity and mortality, it causes an enormous 
socioeconomic burden6,7. The significant morbidity attached to 
aSAH can be attributed to rebleeding, delayed cerebral ischaemia 
(DCI), hydrocephalus, and other medical complications, despite 
successful treatment of the ruptured aneurysm. Of these complica-
tions, DCI is the most important cause of morbidity and mortality 
in patients who survive the ruptured aneurysm5,8,9. Between days 
3 and 10 after the initial aSAH, 30–40% of patients will suffer DCI 
and half of these will have a poor outcome5,10,11.
Our understanding of DCI is meagre at best. Conventionally, DCI 
was thought of as a neurological deficit observed at least three days 
after aSAH with radiological confirmation of large vessel narrowing 
and was often termed “vasospasm”. However, more contemporary 
articles question whether the relationship between angiographic 
cerebral vessel narrowing and neurological outcome is associative 
rather than causative and have highlighted the possibility of a mul-
tifactorial aetiology12–15. One of the problems with the disease and 
research surrounding DCI is the terminology applied. Terms include 
DCI, delayed ischaemic neurological deficit (DIND), delayed neu-
rological deficit, secondary cerebral ischaemia, and vasospasm. In 
2010, a consensus statement was issued defining DCI as a focal 
neurological impairment or decrease of ≥2 points on the Glas-
gow Coma Scale which lasts for ≥1 hour, is not apparent imme-
diately after aneurysm occlusion, and cannot be attributed to other 
causes by means of clinical assessment, blood tests, or imaging16. 
The Neurocritical Care Society’s consensus definition was similar 
for DCI and also defined vasospasm as radiological evidence of 
cerebral vessel narrowing with corresponding neurology17.
Cerebral artery narrowing
Over six decades ago, cerebral vessel narrowing was demonstrated 
by angiography after aSAH18. A decade later, a link was found 
between cerebral vessel narrowing and focal neurology19. Then 
in the late 1970s, it appeared that vessel narrowing was not only 
localised to the vascular territory of the aneurysmal bleed but also 
proportional to blood load and occurred between days 3 and 12 
after the aSAH20,21. More contemporary authors found the onset of 
vessel narrowing started on day 3, was maximal by days 6–10, and 
lasted for up to two weeks22–24. The density, duration and volume of 
subarachnoid blood are key predictors of vessel narrowing21,25. Nar-
rowing of cerebral arteries may cause a reduction in cerebral blood 
flow distal to the constricted vessel and contribute to secondary 
ischaemia26. The cause of vessel narrowing after aSAH is unclear 
but is thought to involve oxyhaemoglobin release, an inflammatory-
mediated response, decreased nitric oxide levels, and an increased 
concentration of endothelin-1 (ET-1)14.
Oxyhaemoglobin
Oxyhaemaglobin induces cerebral artery vasoconstriction in vitro 
and in vivo in primates, which is not seen with methaemoglobin 
or bilirubin27–29. It is thought that oxyhaemoglobin decreases the 
production of prostacyclin and increases prostaglandin E2 in ves-
sel walls, thereby causing vasoconstriction. It can also inhibit 
endothelial-dependent relaxation. The oxidation of oxyhaemoglobin 
to methaemoglobin, which occurs spontaneously, causes lipid per-
oxidation and vasoconstriction30. It is plausible that oxyhaemo-
globin causes vasoconstriction by some or all of these mechanisms 
but attempts at modulating them have not completely reversed ves-
sel narrowing or, importantly, improved outcomes.
Nitric oxide
Nitric oxide, which is responsible for the relaxation of vascu-
lar smooth muscle cells, appears to be depleted after aSAH. This 
may be due to a number of reasons, one of which is that nitric 
oxide is scavenged by haemoglobin, released during the break-
down of subarachnoid blood, due to nitric oxide’s high affinity for 
haemoglobin31,32. In addition to this, the production of nitric oxide 
may also be decreased due to the down-regulation of endothelial 
and neuronal nitric oxide synthase, which occurs in spastic arteries 
after aSAH33–35. Both of these mechanisms will lead to a decrease 
in the bioavailability of nitric oxide, which is then unable to coun-
teract the effects of the vasoconstrictor ET-136. Furthermore, exog-
enous donors of nitric oxide, such as sodium nitroprusside and 
nitroglycerin, although associated with systemic side effects, have 
been shown to ameliorate cerebral artery narrowing37,38. In addi-
tion to the hypotension seen with these exogenous donors, there is 
also a concern that exposing nitric oxide to oxyhaemoglobin and 
deoxyhaemoglobin will lead to the formation of methaemoglobin, 
S-nitrosohaemoglobin and ferrous-nitrosyl-haemoglobin33. Inter-
estingly, Kida et al. note in their comprehensive review that inhaled 
nitric oxide acts as a selective pulmonary vasodilator and avoids 
the hypotension seen with intravenous administration. Animal 
studies have demonstrated a reduction in ischaemia-reperfusion 
injuries after nitric oxide inhalation in extrapulmonary organs after 
cardiac injury. These have also been supported by proof-of-concept 
human trials39. The research discussed is used to support post-cardiac 
arrest ischaemia but Garry et al. also encourage further investiga-
tion of nitric oxide as a treatment of secondary brain injury in their 
review with reference to aSAH40.
Endothelin
Endothelin is key to maintaining the vascular tone of blood vessels, 
with ET-1 being the most potent endogenous activator of vasocon-
striction. The amount of ET-1 in serum and plasma increases within 
minutes after the aSAH and peaks around days 3–4, the time at 
which DCI starts to occur. There also appears to be an excessive 
release of ET-1 by astrocytes around the time of onset of ischaemic 
symptoms41,42. ET-1 concentrations appear consistently elevated in 
patients with DCI. However, there are conflicting reports of ET-1 
concentrations within the normal range in patients with radiologi-
cal evidence of cerebral artery narrowing who do not have DCI43–45. 
Authors have questioned whether increased ET-1 marks ischaemic 
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damage rather than arterial vessel narrowing in DCI14. Therefore, 
there are a number of different mechanisms that could be contribut-
ing to the arterial narrowing commonly seen after aSAH.
Alpha calcitonin gene-related peptide
Alpha calcitonin gene-related peptide (CGRP) is an endogenous 
neuropeptide and a potent vasodilator. CGRP exhibits its vasodi-
lating properties by two mechanisms: one is nitric oxide and 
endothelium-dependent and the other is cyclic adenosine mono-
phosphate mediated and is endothelium-independent46. Endogenous 
CGRP appears to be released, and is subsequently depleted, after 
aSAH to combat cerebral vasoconstriction which has led to the the-
ory that exogenous CGRP may be beneficial in managing DCI47–49. 
Because CGRP can act independently of endothelial cells, which are 
morphologically damaged after aSAH, it may be successful in treat-
ing DCI. A number of animal studies and three human trials have 
investigated the effect of CGRP on cerebral arteries after aSAH. 
All animal studies appear to show either a reversal or improve-
ment in cerebral artery narrowing46. The largest human trial, the 
European CGRP in aSAH study, demonstrated little improvement 
in morbidity or mortality from intravenous administration but noted 
that systemic side effects, such as hypotension, were limiting and 
suggested that intrathecal administration may be more beneficial, 
as endogenous CGRP acts on the abluminal side of vessel walls50. 
A trial investigating the effect of CGRP after intrathecal administra-
tion is still awaited.
Radiological evidence
An often-cited argument against cerebral vasoconstriction being a 
causative factor of DCI is that, whilst up to 70% of patients demon-
strate cerebral vessel narrowing on angiography, only 40% of these 
will manifest neurological deficits and only 30% develop DCI51–54. 
However, it must be acknowledged that even the consensus defi-
nition of DCI provided in the introduction has its limitations16. 
Patients with poor grade aSAH (World Federation of Neurosurgical 
Societies Grades IV and V), the group of patients most likely to 
develop DCI, are often sedated and mechanically ventilated and 
are particularly difficult to assess clinically55. Therefore, it is likely 
that we are under-diagnosing and under-treating DCI in this group 
of patients. Furthermore, it may be that the degree of large cer-
ebral vessel narrowing does not correlate well with symptom 
severity26.
Following a review of current tests available for the diagnosis of 
delayed cerebral ischaemia, Rodriguez et al. advise clinical exami-
nation and transcranial Doppler (TCD) in the screening and diag-
nosis of “vasospasm”. The authors reserve multi-modal magnetic 
resonance imaging (MRI) and computed tomography (CT) for spe-
cific situations, and acknowledge digital subtraction angiography 
(DSA) as the gold standard for diagnosis (Figure 1)56. Rabinstein 
et al. found that TCD and angiogram demonstrating cerebral vessel 
narrowing (termed vasospasm) only had a positive predictive value 
of 67% for cerebral infarction on CT8. We would expect this to be 
higher if cerebral vessel narrowing was the primary cause of DCI. 
Rates of cerebral infarction in patients with evidence of cerebral 
vessel narrowing range between 24 and 35% using CT57,58, but have 
been found to be as high as 81% in some studies using MRI59. In 
addition to this poor correlation between cerebral vessel narrowing 
and infarction, there is clinical evidence that up to 25% of delayed 
infarcts on CT are not in the same territory as the vessel narrowing, 
or are found in patients that did not demonstrate vessel narrowing at 
all60–62. Rabinstein et al. note that TCD and angiogram only agreed 
on the diagnosis of “vasospasm” in 73% of cases and so it could be 
that vessel narrowing simply wasn’t identified in patients who were 
later found to have evidence of infarcts on CT8. Despite these con-
flicting messages, clinical studies do report that those patients with 
radiological evidence of cerebral vessel narrowing are at greater 
risk of DCI62,63.
Herz et al. directly visualised pial artery constriction after applica-
tion of blood or microtrauma to pial arteries in animal studies64. 
Further in vitro research has suggested that constriction of intra-
parenchymal arterioles occurs after aSAH and may contribute to 
DCI65. Maximal luminal narrowing has been seen between days 
3 and 7 and repeated in vivo in mouse studies. The correlation 
between decreased regional cerebral blood flow and microvascu-
lar constriction appears stronger than that seen with large vessel 
narrowing65–67. Uhl et al. identified constriction of small vessels 
in surgical patients within the first 72 hours after aSAH by spec-
tral imaging, and Pennings et al. later directly observed cerebral 
arterioles contracting after aSAH68,69. Therefore, it may be that ves-
sel narrowing is consistently occurring with DCI but that we are not 
visualising it because it is microvascular and not readily visible on 
catheter angiography or TCD56.
CT perfusion scanning (CTP) may provide haemodynamic evidence 
to support the diagnosis of DCI. Dankbaar et al. evaluated the diag-
nostic value of CTP for DCI and reported 84% sensitivity, 79% spe-
cificity, and 88% positive predictive values70. Sanelli et al. found 
that more CTP deficits occurred in patients with DCI than in those 
Figure 1. CT image of subarachnoid haemorrhage. Non-contrast 
CT scan of brain showing subarachnoid haemorrhage in classical 
“star sign” distribution with blood distributed along basal vessels.
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without71. Dankbaar et al. later suggested that patients with DCI 
exhibit worse cerebral perfusion (measured on CTP) than patients 
without DCI even before focal signs occurred. Encouragingly, they 
demonstrated partial recovery in areas of poor perfusion, suggesting 
that DCI could be partly reversible72. However, Killeen et al. concluded 
from their retrospective comparative study that CTP and DSA had 
similar test characteristics for identifying DCI in aSAH patients73.
Endothelin-antagonists
A shift in theory from cerebral vessel narrowing to a multifacto-
rial aetiology occurred after the CONSCIOUS trials and a recent 
meta-analysis of pharmacological treatments for delayed cerebral 
ischaemia74–76. The meta-analysis demonstrated that, despite a 
reduction of cerebral vessel narrowing, no statistically significant 
effect on poor outcome was observed74. However, the authors note 
that the dissociation between a reduction in cerebral vessel narrow-
ing but not poor outcomes could result from methodological prob-
lems, sample size, and insensitivity of outcome measures, in addi-
tion to a multifactorial aetiology of DCI. The CONSCIOUS trials 
were multicentre randomised controlled trials (RCT) investigating 
the effect of clazosentan, an endothelin-A (ET-A) antagonist, on 
“vasospasm” after aSAH. The first of these trials, CONSCIOUS-1, 
demonstrated that, despite a significant reduction in angiographic 
cerebral vessel narrowing, there was little evidence to support 
its use to improve morbidity and mortality and it was associated 
with increased rates of pulmonary complications, hypotension and 
anaemia76. CONSCIOUS-2 demonstrated no benefit from clazosen-
tan in patients treated with surgical clipping, which led to the early 
termination of the trial75. Laban et al. recently published a review 
of animal studies investigating endothelin receptor antagonists 
after experimental aSAH and found no improvement in functional 
outcomes77. Perhaps more importantly, the review described insuf-
ficient animal data supporting endothelin receptor antagonists to 
warrant progression to a human trial. The authors also suggest that 
cerebral artery diameter, or “vasospasm”, is not a clinically relevant 
outcome measure in experimental aSAH studies77.
The example of clazosentan appears to provide evidence that 
cerebral artery narrowing is not the sole cause of DCI. However, 
there is conflicting evidence as more invasive methods of reduc-
ing vessel narrowing can improve outcomes (Figure 2). Kimball 
et al. reviewed 49 articles relating to interventional techniques 
to treat “vasospasm”. A total of 24 of the 27 publications (1,028 
patients) reporting the use of transluminal balloon angioplasty 
noted an improvement in vessel diameter and neurological deficits. 
Twelve case series reported good angiographic and clinical results 
for patients who received papaverine (a vasodilator) administered 
approximate to the site of vessel narrowing78. Both techniques were 
associated with significant side effects and the quality of the studies 
was reported as very low to moderate (based upon the GRADE clas-
sification system)79. Nevertheless, the review does provide evidence 
that cerebral artery narrowing is likely to be strongly involved in the 
pathology of DCI.
Nimodopine
The calcium channel antagonist nimodipine is the only proven inter-
vention to reduce the incidence of DCI and improve outcomes after 
aSAH. Nimodopine was initially investigated as a vasodilator in the 
hope that it would aid post-ischaemic reperfusion, as it was thought 
that an increase in calcium in vascular smooth muscle cells led to 
“vasospasm”80,81. In 1989, the British Aneurysm Nimodipine Trial 
subsequently demonstrated a significant reduction in cerebral inf-
arction rates and improved neurological outcomes at three months 
after aSAH82. A Cochrane review in 2007 concurred with these 
findings but noted that the supporting evidence was based mainly 
on one large study. This led to oral nimodipine becoming standard 
care for patients after aSAH83. Interestingly, the review found no 
statistically significant results to support the use of other calcium 
antagonists, magnesium sulphate, or intravenous administration of 
nimodipine.
Magnesium sulphate is a non-competitive inhibitor of calcium 
channels and has vasodilatory and neuroprotective properties, simi-
lar to nimodipine. Hypomagnesaemia is common in patients after 
aSAH, appears to be proportional to the severity of the bleed, and 
is predictive of DCI84. Magnesium sulphate has also been shown 
to reduce cerebral artery narrowing and the size of ischaemic 
lesions after aSAH in animal models85. However, the Neurocritical 
Care Society guidelines advise against the routine administration 
of magnesium in patients with aSAH17. This is supported by data 
from the intravenous magnesium sulphate for aneurysmal sub-
arachnoid haemorrhage (IMASH) and MASH-2 trials and a recent 
meta-analysis demonstrating no beneficial effect of magnesium in 
this group of patients86–88. A post hoc analysis of the IMASH trial 
reported an association between high plasma levels of magnesium 
and worse clinical outcomes89.
In summary, one calcium channel antagonist, nimodipine, has 
been shown to be effective in the prevention and treatment of 
DCI after aSAH whilst other calcium channel antagonists and a 
non-competitive inhibitor of calcium channels appear to have little 
effect on, or worsen outcomes.
It remains unclear how nimodipine exerts its neuroprotective effects 
but its action seems independent of any effect on large vessel 
narrowing90,91. It was thought that nimodipine may exert its effect 
by stopping calcium influx at a neuronal level, but no beneficial 
effect has been seen from administration in patients after ischae-
mic stroke or traumatic brain injury92–94. In addition to this, a recent 
systematic review found no benefit from nimodipine after traumatic 
SAH, suggesting that the mechanism of action of nimodipine is 
unique to aSAH95. Nimodipine has two properties that it does not 
share with other calcium channel antagonists. Firstly, it increases 
endogenous fibrinolytic activity, which may reduce the incidence 
of microthrombosis96. Secondly, it antagonises cortical spreading 
ischaemia in rats, which may be one of the culprits in DCI and is 
discussed in further detail below97.
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Contemporary hypotheses
Early brain injury
Early brain injury (EBI) refers to damage to the brain in the first 
72 hours after the haemorrhage. There are a number of patho-
physiological events in this time period that could influence later 
complications, such as DCI, and much of our understanding is 
derived from experimental data. One of these changes is a severe 
rise in intracranial pressure leading to decreased cerebral perfusion 
pressure, cessation of cerebral blood flow and ultimately global 
ischaemia and oedema98–100. The intracranial hypertension at ictus 
is often greater than systolic blood pressure, and the rate of increase 
and peak intracranial pressure appears to be proportional to the 
amount of arterial blood extravasating into the subarachnoid spaces 
from the aneurysm101–103. Cerebral spinal fluid outflow obstruc-
tion, in addition to hydrocephalus, further exacerbates intracranial 
hypertension104,105. However, the increase in intracranial pressure is 
not uniform and there are two distinct groups of patients in terms of 
their intracranial hypertension. The first, more common, scenario 
is an increase in intracranial pressure to the arterial diastolic pres-
sure which then decreases to just above the patient’s baseline intrac-
ranial pressure102. These patients typically have a small volume 
haemorrhage with cerebral oedema. The second type of increased 
intracranial pressure is sustained due to either a progressive hae-
matoma or acute hydrocephalus104,105.
The cerebral oedema seen after aSAH is often present on admission 
CT scans and becomes more common, being present in up to 20% 
of patients by day 698. Cerebral oedema is itself a poor prognostic 
factor after aSAH98,106,107. The global cerebral ischaemia that occurs 
during the initial aSAH may lead to the disruption of the blood-
brain barrier, and initiate cell death mechanisms and inflammatory 
responses which all contribute to cerebral oedema. Regulated and 
Figure 2. Angiograms demonstrating cerebral vessel narrowing after subarachnoid haemorrhage. A and B: Anteroposterior (A) and 
lateral (B) angiograms of the left internal carotid artery demonstrate vessel narrowing at the level of the carotid siphon, the terminal internal 
carotid artery, the A1 segment of the anterior cerebral artery and the middle cerebral artery. C and D: Anteroposterior (C) and lateral (D) 
angiograms obtained after intra-arterial injection of nimodipine.
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unregulated neuronal cell death appears to occur within 24 hours 
after aSAH and as early as 40 minutes after the initial injury108–110. 
Serum and cerebrospinal fluid (CSF) levels of pro-inflammatory 
cytokines and vasoactive factors, such as tumour necrosis factor-α, 
interleukin-6, and interleukin-1 receptor antagonist, correlate with 
DCI and poor outcomes111,112.
In addition to these inflammatory responses, blood degradation 
products are thought to contribute to DCI and perhaps removing 
blood from the subarachnoid space may improve outcomes30,113. 
Continuous cisternal drainage and intrathecal administration of 
thrombolytics have been trailed with reports of success, and results 
of the EARLYDRAIN trial comparing continuous lumbar-CSF 
drainage with standard treatment are awaited114,115. A meta-analysis 
of the use of intrathecal thrombolytics suggested a reduction in the 
incidence of DCI but these findings were not statistically significant 
after excluding one study, which included intrathecal nimodipine in 
addition to thrombolytic therapy116.
Cerebral autoregulation, the ability of blood vessels to maintain 
constant cerebral blood flow (CBF) with arterial blood pressures 
between ~60 and 150 mmHg, is impaired after the aneurysm 
rupture117–119. Once impaired, autoregulation starts to rely on cer-
ebral perfusion pressure and blood viscosity. Because of this, any 
change in intracranial pressure or systemic arterial pressure can 
potentially worsen oedema and ischaemia.
A limitation to many of these theories is that the majority of data 
comes from animal studies of experimental aSAH models. Some 
authors have questioned whether we can reliably translate data 
derived from this model to human studies120,121. We await the results 
of a systematic review and meta-analysis of intracranial in vivo 
animal studies of EBI and delayed cerebral arterial vessel narrow-
ing after aSAH122. The review aims to analyse aSAH models and 
define standard experimental parameters and endpoints for the 
study of EBI after aSAH and aSAH models of delayed cerebral 
arterial vessel narrowing.
Cortical spreading depolarisation
Cortical spreading depolarisation (CSD), also termed cortical 
spreading depression, reflects a wave of depolarisation that spreads 
across grey matter at 2–5 mm/min. CSD is not a new theory, nor is 
it limited to aSAH, and has been implicated in brain injuries and 
migraine123. It occurs when a cation influx across cellular membranes 
exceeds the Na+ and Ca2+ pump action and is followed by water and 
shrinkage of the extracellular space by ~70% causing depression of 
EEG (electroencephalography) activity124,125. Because the Na+ and 
Ca2+ pump is ATP-dependent, to counteract the passive influx of 
cations across the membrane energy consumption increases, which 
leads to increased regional blood flow requirements. When there 
is a dysfunction of the vasculature in the region, as occurs after 
aSAH, severe microvascular spasm can occur, rather than vasodila-
tion, causing “cortical spreading ischaemia”125. There is evidence 
that CSD occurs after the initial aneurysm rupture from both ani-
mal and human studies, and it is thought that after each depolarisa-
tion hypoperfusion of the cortex occurs due to vasoconstriction126. 
Furthermore, up to 75% of all CSD episodes occur between days 
5 and 7 after the aSAH, which matches DCI chronology127. Another 
link between CSD and DCI comes from the CoOperative Study on 
Brain Injury Depolarisations (COSBID), which demonstrated that 
repeated CSD preceded DCI with little evidence of “vasospasm” 
on digital subtraction angiography (DSA), albeit in a small sample 
(thirteen patients)128.
Microthrombosis
Increased levels of procoagulants have been seen prior to DCI, spe-
cifically an increased von Willebrand factor 72 hours after aSAH 
and increased platelet-activating factors on day 4129–132. Micro-
thrombi have also been identified at the autopsy of patients after 
aSAH, suggesting that they are involved in aSAH pathology132. The 
rate of rebleeding following aSAH has been significantly reduced 
following tranexamic acid administration. However, it may have led 
to an increased incidence of DCI separate from large vessel nar-
rowing, possibly because the antifibrinolytic therapy caused micro-
thrombosis and promoted DCI133–136. Unfortunately, the results of 
studies investigating antiplatelet agents in the treatment of micro-
thrombosis after aSAH have been largely negative, including those 
investigating prophylactic low-molecular-weight heparin137,138.
Therapies
Intrathecal therapies
Intrathecal administration of nicardipine, a dihydropyridine calcium 
channel blocker, has been demonstrated in a number of clinical 
studies with varying results. Susuki et al. examined a series of 177 
patients with Fisher grade III aSAH undergoing aneurysmal clip-
ping and cisternal drainage within 48 hours of the aSAH139. Patients 
received 4 mg intrathecal therapy nicardipine every 12 hours 
on days 3–14 postoperatively. Of these patients, 11.3% had radio-
graphic evidence of vessel narrowing and 5.7% had clinical signs 
of DCI. The authors note a significant reduction in “vasospasm” 
but also recognise that 18.6% of patients required a shunt opera-
tion. Shibuya et al. demonstrated a decreased incidence of DCI and 
angiographic vessel constriction by 20 and 26% respectively after 
prophylactic administration of 2 mg intrathecal therapy nicardipine 
via a cisternal drain when compared with control patients140. More 
recent trials also report positive findings, but are limited to cases 
of refractory “vasospasm” and have very small sample sizes141,142. 
However, nicardipine is associated with probable vasodilation-
associated headaches, intracranial infections and hydrocephalus, 
and positive long-term outcomes from large RCTs are lacking. 
The NEWTON trial is a phase I/IIa multicentre RCT administer-
ing intrathecal nimodipine in patients with aSAH143. The trial uses 
EG-1962, a sustained delivery system of nimodipine in micropar-
ticles. These will be injected into the ventricles through an exter-
nal ventricular catheter in patients undergoing coiling or clipping 
of ruptured aneurysms. It is thought that systemic effects are less 
likely to occur as nimodipine concentrations are much lower in the 
plasma than CSF144. We await the results of this trial and subsequent 
progressive trials with interest.
Pleiotropic interventions
Statins have been investigated as a potential treatment for DCI due 
to their multiple effects, although a recent meta-analysis of the 
four single-centre RCTs demonstrated no benefit from statins after 
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aSAH145. Despite evidence that statins can reduce the duration of 
impaired autoregulation after aSAH, two more recent multicentre 
RCTs found no benefit from statin administration after aSAH146–148.
Another potential agent in the treatment of DCI is cilostazol, a 
phosphodiesterase 3 inhibitor and platelet aggregation inhibitor 
that affects smooth muscle cells. A meta-analysis of two RCTs and 
two quasi-RCTs demonstrated amelioration of cerebral vessel nar-
rowing and a benefit on outcome at discharge, even after excluding 
the lower quality studies149–151. A subsequent trial has echoed these 
findings, but only one study has reported long-term outcomes and 
did not demonstrate improved outcomes with cilostazol151,152.
Conclusion
In summary, cerebral vessel narrowing is consistently seen after 
aSAH, but its location and severity is not predictably linked to 
DCI. There is no conclusive evidence to support the treatment 
of vessel narrowing in the management of DCI, despite some 
studies reporting improved outcomes, specifically after more inva-
sive techniques. Nimodipine is the only effective treatment for DCI 
but we still do not understand how nimodopine exerts its neuro-
protective effect, although it does not seem to work by reversing 
cerebral artery narrowing, at least not in large vessels. It is pos-
sible that we are not detecting microvascular vasoconstriction or 
ischaemia on CT and TCD and so our understanding of the pathol-
ogy is limited. Furthermore, improved recognition of DCI clini-
cally, from imaging and/or biochemical markers would not only 
allow for quicker treatment but also better assessment of interven-
tions. DCI almost certainly has a multifactorial aetiology and it 
may be that only by combining interventions will we see improved 
outcomes, but first we must understand the aetiology. Understand-
ing how nimodipine, the only drug with proven efficacy, exerts its 
effect may be the key to creating new interventions with improved 
efficacy. There remains a large amount of work to be done in under-
standing DCI and investigating future potential treatments.
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